MBS significantly reduces liver-related complications and other health risks in patients with SLD, including cardiovascular, ...

Marcus Flores, PharmD, BCPS, BCOP, discusses the vital role of pharmacists in multidisciplinary cancer care, exploring ...

US-based patients with idiopathic pulmonary fibrosis (IPF) had a slower decline in forced vital capacity (FVC) when they received nerandomilast (Jascayd; Boehringer Ingelheim) compared with placebo, a ...

Panelists discuss how schizophrenia presents a wide spectrum of symptoms categorized into positive, negative, and cognitive ...

Panelists discuss how: clinical inertia, patient apathy, and the asymptomatic nature of high cholesterol all contribute to undertreatment and poor outcomes.

Panelists discuss how: LDL-C control remains a national crisis, with many patients not on therapy or failing to reach target ...

Panelists discuss how schizophrenia’s immense personal and financial burden calls for early, integrated, and sustained care ...

MOG-IgG positivity is rare in MS patients, complicating diagnosis and treatment, especially in Asian populations with lower ...

Across studies, the rate of sudden death in ibrutinib-treated patients ranged from 0.49 to 0.788 per 100 patient-years, roughly double that seen in comparators. In contrast, pooled analyses of ...

Mortality rates for pneumonia and pulmonary fibrosis have declined since 1999, but disparities persist by sex, race, and ...

A biomarker panel for IPF may identify RA patients at higher risk for ILD, supporting biological overlap between IPF and ...

Nicoletta Colombo, MD, PhD, of the University of Milan-Bicocca, discussed the rationale behind paclitaxel with bevacizumab ...